SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 5, 2002; DOI 10.1182/blood-2002-07-2139. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-07-2139v1 101/3/943    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sallah, S. Articles by Wan, J. Y. Search for Related Content PubMed PubMed Citation Articles by Sallah, S. Articles by Wan, J. Y. Related Collections Hemostasis, Thrombosis, and Vascular Biology Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 February 2003, Vol. 101, No. 3, pp. 943-945 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Brief report Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia Sabah Sallah and Jim Y. Wan From the Thrombosis and Hemostasis Program and Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA; and the Department of Preventive Medicine, University of Tennessee Health Sciences Center, Memphis. The authors examined the efficacy of 2-chlorodeoxyadenosine (2-CDA) in the treatment of refractory inhibitors to factor VIII in persons without hemophilia. The drug was administered to 6 patients at a dose of 0.1 mg/kg as a 24-hour continuous infusion for a total of 7 days each cycle. An average of 3 immunosuppressive regimens per patient had been administered prior to enrollment in this study. The median inhibitor titer against human and porcine factor VIII before treatment with 2-CDA was 31 Bethesda units (BUs) and 9 BU, respectively. The median inhibitor titer against human and porcine factor VIII after treatment was 3.5 BU and 1.5 BU, respectively. The median time to reach nadir inhibitor titer in this study was 137 days, whereas the median time to reach a 50% increase in factor VIII was 117 days. No major toxicity was observed in any patient in this study. Patients with acquired inhibitors to factor VIII refractory to conventional immunosuppressive therapy may respond favorably to 2-CDA. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. R. Sperr, K. Lechner, and I. Pabinger Rituximab for the treatment of acquired antibodies to factor VIII Haematologica, January 1, 2007; 92(1): 66 - 71. [Abstract] [Full Text] [PDF] A. D. Ma and D. Carrizosa Acquired Factor VIII Inhibitors: Pathophysiology and Treatment Hematology, January 1, 2006; 2006(1): 432 - 437. [Abstract] [Full Text] [PDF] P W X Foley, D Pepperell, R. Kazmi, and N P Curzen Unsuspected acquired haemophilia in a patient with myocardial infarction J R Soc Med, November 1, 2004; 97(11): 542 - 543. [Full Text] [PDF] K.-G. Fischer, B. Deschler, M. Lubbert, A. Wiestner, B. B. Weksler, and G. P. Schechter Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses Blood, May 1, 2003; 101(9): 3753 - 3754. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020